Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Trial Profile

Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 24 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Jul 2015 According to Ohr Pharmaceuticals media release, at week 38, the mean gain in visual acuity from baseline for patients randomized (at week 10) to treatment with OHR-102 + Lucentis PRN was +27.8 letters compared with +23.3 for patients randomized to treatment with Lucentis plus PRN alone (control group), a clinically meaningful difference of +4.5 letters.
    • 13 Jul 2015 According to Ohr Pharmaceuticals media release, data from this trial has been presented at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top